Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers identified kynurenine and indoxyl sulfate as key culprits in generating clot formation in cancer patients via AHR signaling. These metabolites can be measured in the blood to predict risk of deep vein thrombosis, and their inhibition may lead to future drug development.
A phase III study shows that HLX02, a Chinese-made biosimilar of trastuzumab, has an overall response rate of 71% at week 24, comparable to the reference medication. The treatment is safe and effective, with similar rates of adverse events and no differences in safety profiles or immunogenicity.
Acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, has been approved by the FDA for first-line therapy in chronic lymphocytic leukemia (CLL) and small cell lymphoma (SML). The drug works by permanently binding to BTK, halting cancer cell growth signals.
Researchers found that extra DNA surrounding cancer-causing genes is crucial for maintaining their activation and supporting tumor growth. This discovery could explain why some cancer treatments are effective while others fail, and may lead to new therapeutic strategies.
Researchers at UTSA are developing new methods to synthesize organosulfur compounds, which are widely used in pharmaceuticals. The goal is to improve the accuracy and speed of these synthesis processes, leading to more effective medicines and potentially advancing functional materials.
The University of Illinois Chicago will help young breast cancer survivors navigate post-treatment care and survival with a $1.8 million CDC grant. The program aims to reduce disparities in survival and quality of life due to social factors among breast cancer survivors.
Researchers identified a panobinostat-marizomib combination that effectively kills childhood brain cancer cells and counters genetic mutations. The study uncovered a previously unrecognized vulnerability in cancer cells, which may lead to new strategies against the disease.
Researchers at Cold Spring Harbor Laboratory have developed a new therapy that extends the survival of mice with acute myeloid leukemia by blocking the Salt-Inducible Kinase 3 (SIK3) pathway. The treatment, YKL-05-099, is a first in demonstrating anti-cancer effects of SIK3 inhibition using pharmacological blockade.
Researchers identified molecular mechanisms underlying the lack of efficiency of nintedanib in squamous cell carcinoma and found smoking to be a key factor. The study suggests patients with adenocarcinoma may benefit from antifibrotic drugs like nintedanib combined with radiotherapy or immunotherapy.
The National Foundation for Cancer Research has named the winners of its Salisbury Award Competition, recognizing innovative cancer research projects. The winning project, led by Emily Han-Chung Hsiue and Jacqueline Douglass, targets cancer driver mutations with a novel antibody-based method.
The new guidelines call for better access to CDK4/6 inhibitors and anti-HER2 therapies for patients with advanced breast cancer. Experts also stress the need for adequate pain control, particularly in countries where opioids are scarce or misused.
Scientists at Sanford Burnham Prebys Medical Discovery Institute identified a combination of two anti-cancer compounds that shrank pancreatic tumors in mice, supporting the immediate evaluation of the drugs in a clinical trial. The study provides rationale for an immediate clinical trial evaluating the 2 therapies
Scientists at UCLA Jonsson Comprehensive Cancer Center developed a new high-throughput screening system that identifies selective inhibitors of metabolic pathways. The approach revealed multiple kinase inhibitors block nucleotide metabolism and its targets.
A new study finds that nearly half of 50- to 64-year-olds think they're likely to develop dementia, but only 5% have talked to a doctor about reducing their risk. Meanwhile, many use unproven tactics like supplements and brain games to stave off the disease.
The study found that T-DM1 resulted in a third of patients experiencing objective response and nearly 40% continuing treatment for at least six months. Patients with central nervous system metastases had shorter progression-free survival rates, highlighting the need for inclusion in randomized trials.
Researchers at Princess Margaret Cancer Centre have identified new protein targets for drug development against prostate cancer by analyzing noncoding DNA regions. These regions, previously thought to be 'junk' DNA, were found to harbor important regulatory elements that determine gene expression.
A novel mathematical framework has been developed to map out precisely how different perturbations of the interactome influence each other. The study reveals that the position of targets of a given drug on the interactome is not random but rather localized within drug modules.
A new biomarker, plectin, has been identified in cancer stem cells, which govern cancer survival and spread. Plectin's translocation onto the cell surface is linked to tumor invasion and metastasis, making it a potential target for drug development.
A study published in JAMA reports that cardiac resynchronization therapy can significantly improve heart function in cancer survivors with congestive heart failure. After six months, the patients experienced improved heart function, reduced symptoms, and enhanced quality of life. The therapy offers a possible solution for patients who ...
Biomedical engineers have combined ultrafast ultrasound imaging with ultrasonic tweezers to precisely track and target drug carriers within a phantom blood vessel. This new method could enable acoustic control and real-time tracking of drug release within the body, potentially improving targeted therapeutics.
Purdue University scientists have identified key changes in the blood-brain barrier that hinder effective drug delivery to brain tumors. The discovery aims to improve treatment plans and patient outcomes for those with brain metastases from breast, lung, and melanoma.
Researchers at the University of Michigan developed a small-molecule compound that harnesses the power of a natural cellular cleanup system to eliminate tumors. The degrader achieved nearly complete elimination of tumors in mouse models of leukemia and lymphoma, with lasting results.
Researchers at Texas Tech University Health Sciences Center have developed a novel drug combination using fenretinide and venetoclax to treat high-risk neuroblastoma. The study found that the combination of these two drugs showed significant activity against neuroblastoma cells, with multiple complete responses achieved in patients.
Scientists designed a novel approach to create stable and predictable antibody drug conjugates (ADCs) using computational docking molecular simulations. The new therapy, called MAGNET-ADC, can deliver cancer drugs specifically to tumor tissue with reduced toxicity.
Researchers identify a potential target for eliminating leukemia stem cells using vitamin K3, which stabilizes the DYRK2 enzyme. This approach could lead to treatment-free remissions and improved patient outcomes.
City of Hope researchers have created a modified CRISPR gene editing tool that improves the accuracy and efficiency of cutting out undesirable genetic information. The new design has shown promise in treating HIV and sickle cell disease by increasing desirable mutations and improving activity at specific target sites.
Dr. Yamamoto received the prestigious Karl Landsteiner Memorial Award and Lectureship for his work on blood group genes. He has contributed to a better understanding of glycosylation polymorphisms and cancer-specific glycosylation alterations.
Nami Therapeutics develops nanoparticles for targeted drug delivery, offering increased efficacy and reduced toxicity. The platform selectively targets ovarian cancer metastasis in the peritoneal cavity, improving survival rates.
A new USC study reveals that mint is the most popular flavor among U.S. teens who vape, contradicting previous studies that linked fruit flavors to teen vaping. The findings cast doubt on the effectiveness of JUUL's voluntary product removal and federal regulations aimed at reducing youth vaping.
Researchers identified four distinct immune-based subtypes of kidney cancer, which could help predict patient survival and response to treatment. The study also found that certain tumor microenvironment signatures were associated with better or worse overall survival.
The UCLA prostate cancer program has been awarded an $8.7 million SPORE grant to develop new approaches for improving diagnosis, prognosis, and treatment of prostate cancer. The grant will fund three translational research projects to find better ways to treat men with advanced stages of the disease.
A new study finds that acute kidney injury affects 17% of patients taking immunotherapy medications for cancer, while proton pump inhibitors increase the risk of sustained AKI. Nephrologists and oncologists must recognize these factors to diagnose and treat patients effectively.
Researchers at Rice University and MD Anderson Cancer Center have discovered a combination of drugs that target mitochondria can selectively kill leukemia cells while leaving healthy blood cells unaffected. This breakthrough could lead to more effective personalized treatment for patients with leukemia.
A modified Mycobacterium bovis Bacillus Calmette et Guérin (BCG) vaccine, dubbed dBCG, has been shown to be safer and more effective than traditional BCG therapy for bladder cancer. The new approach involves injecting dBCG directly into bladder cancer tumors to reduce recurrence and progression of the disease.
Gabapentinoid prescriptions for adults with cancer grew from 3.3% to 8.3% between 2005 and 2015, with total prescriptions increasing from 1.2 million to 3.5 million. Further study is needed to understand the effectiveness and risks of gabapentinoids in treating cancer pain.
Researchers discovered that Pixantrone interacts with cancer DNA by prising apart the double helix structure and compacting its backbone. This mechanism could lead to the development of more effective cancer drugs with reduced harm to healthy cells.
Researchers at Tohoku University developed a sound-based treatment that delivers anticancer drugs to lymph nodes affected by breast cancer metastases. The technique involves injecting vesicles carrying drugs into the nodes, which rupture when exposed to high-power ultrasound, releasing the medication.
A study by the Eastern Cooperative Oncology Group found that lenalidomide delayed disease progression and improved overall survival in high-risk smoldering multiple myeloma patients. The treatment reduced serious adverse events, but it is unclear if it affects overall survival.
A study by Dartmouth researchers found that a specific genetic subgroup of triple-negative breast cancer and ovarian cancer is vulnerable to heat shock protein 90 (HSP90) inhibitors. This discovery may lead to improved treatment strategies for patients with these cancers.
Researchers at Baylor College of Medicine identified biomarkers that predict poor treatment response in pediatric acute lymphoblastic leukemia (ALL) by analyzing bone marrow metabolomes. Central carbon metabolism pathways were found to be associated with minimal residual disease after treatment.
Researchers at St. Michael's Hospital uncover the molecular process behind protein mutations that cause inflammatory bowel diseases, identifying palmitoylation as key to altering NOD 1 and 2 function. The findings hold promise for potential treatments of inflammatory disorders.
A new study reveals that PGV-1, an analogue of turmeric's curcumin, effectively suppresses tumor cell growth and causes cell death in various types of cancers. The compound's ability to selectively target cancer cells with minimal side effects may lead to breakthroughs in cancer treatment.
A Dartmouth computer scientist has received a $1.5 million grant to develop machine learning approaches that can reveal relationships between clinical and pathologic findings, patient genetic profiles, and drug resistance in non-small cell lung cancer patients. The goal is to provide personalized treatment strategies for NSCLC patients.
Researchers at UNIGE have developed a new formula, C2, composed of four anti-cancer drugs that target and kill tumour cells while leaving healthy cells intact. The formula has shown promising results in reducing the risk of resistance and side effects associated with high-dose treatments.
Researchers developed a targeted cancer treatment using biologically-inspired nanotubes that deliver chemotherapy drugs directly to fast-dividing lung cancer cells. The new technology reduces toxicity and effective kills cancer cells with lower doses, promising a precise approach for precision targeting.
Scientists developed a machine-learning algorithm to automate high-throughput screens of epigenetic medicines, identifying potential treatments for glioblastoma and other diseases. The approach, called Microscopic Imaging of Epigenetic Landscapes (MIEL), detects active drugs and spots epigenetic changes across multiple cell lines.
A USC study reveals that circulating tumor cells have a unique molecular signature that predicts specific organ targets, such as the brain. The discovery provides potential treatment targets to prevent cancer spread and improves detection and monitoring methods.
Researchers have identified a new set of senolytic drugs that can selectively eliminate senescent cells, including those triggered by cancer and irradiation. These compounds, such as ouabain, are repurposed from existing heart medications to treat various diseases, including leukemia and lymphoma.
Researchers have identified a new mechanism by which cancer cells become resistant to ferroptosis, a type of cell death. A molecule called FSP1 acts as a lipid antioxidant, rescuing cancer cells from ferroptosis even when they are starved of GPX4.
Chemists at Ohio State University have discovered a new way to synthesize the most common molecule arrangement in medicine, which could make it easier and more efficient for drug makers to produce medicines. This breakthrough could lead to a reduction in waste and an improvement in the production process.
Researchers at Ohio State University Wexner Medical Center report a measurable increase in inflammation after four weeks of e-cig use without nicotine or flavors. The study suggests that even short-term usage can result in inflammatory changes at a cellular level, a concern as vaping usage is rapidly outpacing scientific understanding.
Researchers found that epigenetic changes allow cancer-promoting genes to interact, leading to drug resistance. The study identified strategies to overcome this resistance using FGFR inhibitors and targeted therapy.
The new guidelines recommend aerobic and resistance training for cancer survivors, aiming to address common side effects such as anxiety and fatigue. The updated recommendations provide specific 'exercise prescriptions' to improve survival rates after a diagnosis of breast, colon, and prostate cancer.
The University of Texas at El Paso's Border Biomedical Research Center will use the grant to understand molecular mechanisms and environmental factors contributing to cancer health disparities in Hispanics. Researchers aim to develop novel treatments using a comprehensive Cancer Tissue Biorepository for this population.
Researchers from Technical University of Munich discovered an inactive receptor in cancer cells prevents checkpoint inhibitors from reactivating the immune system. This leads to a weakened immune response against cancer cells.
Scientists have developed a new class of drug that blocks the APOBEC3B enzyme in cancer cells, which is responsible for treatment resistance. This discovery has the potential to support existing cancer therapies and make treatments more effective by targeting cancer evolution.
Researchers developed a system that allows for spatiotemporal control of CAR T-cell therapy, enabling cancer cells to target specific locations and times. This approach reduces the risk of non-specific targeting of organs and normal tissues, potentially improving treatment outcomes.
Breast cancer survivors who received Acceptance and Commitment Therapy (ACT) showed significant improvements in reducing fear of recurrence compared to other treatment approaches. ACT helps patients focus on living a meaningful life, rather than being driven by fear.
Researchers at Graz University of Technology have created a new method to introduce lipids into proteins, simplifying the process previously employed in medical research. This breakthrough uses a noble metal catalyst and ligand combination to achieve rapid lipidation of cysteine-containing peptides and proteins.
The October issue of SLAS Discovery features a two-part special issue on membrane proteins, highlighting the importance of these targets for novel drug design. The issue includes reviews and original research papers on various aspects of membrane protein biology, such as targeting specific transporters and channels.